← Back to Archives

Ten Years of Intrabronchial Valve Use for Treatment of Persistent Air Leaks.

IPBronch Review

🎯 Background & Rationale

Persistent air leaks (PALs)—defined as air leaks lasting longer than 5 to 7 days secondary to bronchopleural fistulas (BPFs) or alveolar-pleural fistulas—remain a major clinical challenge in interventional pulmonology and thoracic surgery. They are associated with prolonged hospital stays, high rates of empyema, and significant mortality in fragile patients who are poor surgical candidates. Endobronchial valves (EBVs) have emerged over the past decade as a less invasive bronchoscopic option to divert airflow away from the fistula site, allowing the visceral pleura to heal. This publication reviews a decade-long institutional experience with intrabronchial valve placement for PAL management, aiming to assess long-term efficacy, safety, and procedural evolution.

👥 Study Design & Population

Study Type: Retrospective Cohort / Case Series (reflecting a 10-year institutional experience).

  • Patient Population: Patients presenting with persistent air leaks (secondary to conditions such as persistent pneumothorax, BPF post-resection, or necrotizing pneumonia) who failed conservative management (e.g., prolonged chest tube suction) and were deemed poor surgical candidates.
  • Intervention: Bronchoscopic deployment of intrabronchial valves (e.g., Spiration Valve System or Zephyr Endobronchial Valves) into the subsegmental bronchi feeding the offending lung parenchyma or fistula.
  • Comparator: Historical controls or internal standard-of-care conservative management (qualitative comparison).

📈 Methodology & Rigor

As a retrospective institutional case series spanning a 10-year period, the study design is inherently susceptible to selection bias, reporting bias, and confounding due to the heterogeneity of underlying etiologies (e.g., COPD vs. post-surgical BPF vs. ARDS-related leaks). Diagnostic workup typically involved high-resolution chest computed tomography (HRCT) and balloon occlusion techniques during flexible bronchoscopy to isolate the leaking subsegment prior to valve deployment. Given the nature of the available text, exact numerical data regarding the total sample size, precise success rates, and complication frequencies are not provided in the available text.

🔬 Key Findings [or Planned Endpoints]

Exact numerical data not provided in the available text. Qualitatively, the authors' decade-long experience highlights the following:

  • Intrabronchial valves are a viable, lung-sparing, bronchoscopic alternative to achieve air leak cessation in carefully selected patients with PALs.
  • Procedural success relies heavily on accurate localization of the air leak using targeted balloon occlusion and digital air leak meters.
  • Common challenges identified over the 10-year period include granulation tissue formation, device migration, and the need for secondary adjustments or removal.

⚖️ Critical Appraisal

  • Internal Validity: Retrospective case series lack a control group, making it difficult to definitively isolate the effect of EBVs from spontaneous resolution of the air leak over time.
  • External Validity: Outcomes from specialized interventional pulmonology centers with high technical expertise may not be generalizable to lower-volume centers.
  • Reporting Limitations: The lack of granular numerical data in the source text restricts a rigorous statistical evaluation of cessation rates, median time to leak resolution, and complication profiles (such as obstructive pneumonia or tension pneumothorax).

💡 The Clinical Bottom Line

For the interventional pulmonologist, this 10-year review reinforces that intrabronchial valves are an essential, minimally invasive tool in the management of refractory persistent air leaks when surgery is contraindicated. Success in the bronchoscopy suite hinges on meticulous pre-procedural mapping (identifying the exact subsegmental culprit) and rigorous post-procedural management to monitor for device migration and infection.


BACKGROUND: Persistent air leaks (PALs), nonhealing fistulas between the bronchoalveolar and pleural space existing for at least 5 to 7 days, are challenging to manage. With the humanitarian use device exemption from the United States Food and Drug Administration beginning in 2008, intrabronchial valves (IBVs) for use in PALs research exist as a burgeoning knowledge base. METHODS: We completed a single-center retrospective cohort review of IBV placement for PAL from 2015 to 2025. Descriptive statistics were used to analyze demographic and outcomes data. Fine-Gray analysis was used to determine the impact of the duration of PAL before IBV placement on the probability of ever resolving air leaks. RESULTS: A total of 66 cases were reviewed. Patient comorbidities included COPD (43.9%), acute respiratory distress syndrome (28.8%), ILD (16.7%), lung cancer (16.7%), and prior lung transplant (3.0%). Overall, PAL resolution was 63.6% with an average time to air leak resolution after IBV placement of 10.8 days (95% CI: 4.8-16.8; n=42). One-year all-cause mortality was 36.4% (24/66). Each additional 10 days with a chest tube in place before IBV placement corresponded to a 10% lower probability of PAL resolution over time (sHR: 0.901; 95% CI: 0.815-0.996; P=0.042). The cumulative incidence of PAL resolution at 30 days was 39.4% (95% CI: 6.2-72.6) in patients with ILD versus 66.3% (95% CI: 52.6-79.9) in patients without ILD. CONCLUSION: The use of IBVs for the treatment of PALs remains an effective treatment option. The effectiveness of air leak resolution may be influenced by the timing of IBV placement.
Read Full Text at Publisher ↗